QIAGEN NV Q2 FY2024 earnings call

Management Statement and Operational Highlights

• Quarterly Performance: Net sales for Q2 2024 were $496M, +1% at CER vs Q2 2023; adjusted EPS $0.55, $0.03 above outlook. Consumable sales rose 3% CER, making up nearly 90% of total sales.
• Product Advances: QIAstat-Dx launched new panels (e.g., Gastrointestinal Panel 2) and upgraded respiratory panel; QuantiFERON benefited from updated pediatric guidelines for latent tuberculosis screening; phased out NeuMoDx due to post-pandemic market dynamics.
• Financial Update: Updated 2024 outlook: net sales ~$1.985B CER, adjusted EPS raised to $2.16, adjusted operating income margin target 28.5%, with solid free cash flow generation.

Segment Performance

• Sample Technologies: 1% CER growth, driven by strong performance in kits for automation systems (e.g., QIAcube Connect and EZ2 Connect) despite weaker manual kits. Contribution to total sales not specified but part of overall performance.
• Diagnostic Solutions: QuantiFERON sales up 11% CER, marking fifth consecutive quarter above $100M in revenues; QIAstat-Dx grew 12% CER with significant gains in consumables and ongoing instrument placement. QuantiFERON contributes ~52% of its sales in the back half, with QIAstat-Dx stronger in the latter part of the year.
• PCR Nucleic Acid Amplification: QIAcuity had robust consumable sales growth, with demand for higher throughput versions (QIAcuity 4 and 8) popular with biopharma and academia.
• Genomics NGS (QIAGEN Digital Insights): Sales held at high single-digit pace, with expected improvement in the second half due to market demand for bioinformatics solutions.
• NeuMoDx: Phased out, with sales impact considered in guidance, reducing previous sales targets.

Guidance

• Updated 2024 net sales outlook to ~$1.985B CER, reflecting strong first half performance and NeuMoDx phase-out. Adjusted EPS raised to $2.16.
• Q3 2024 net sales outlook at least $495M CER, ~4% CER growth, excluding ~1% headwind from NeuMoDx phase-out, indicating underlying 5% CER growth.

Risks

• Macro Environment: Cautious customer capital investment affecting instrument sales.
• Competition: Impact of competitors in markets like QuantiFERON and NGS, though QIAGEN sees ongoing demand for its solutions.
• Portfolio Optimization: Uncertainties related to phasing out NeuMoDx and evaluating other portfolio components for optimization.

Question and Answer

Q: Catherine Schulte on back half guide and growth A: Thierry Bernard noted execution aligning with initial guidance, with H2 expected to accelerate, driven by new products, QIAcuity diagnostic launch, and QuantiFERON marketing activities.

Q: Michael Ryskin on QIAGEN Digital Insights A: Thierry Bernard discussed bioinformatics market demand for genomics data interpretation, highlighting QIAGEN's AI, automation, and manual curation combination as unique.

Q: Odysseas Manesiotis on margin and instrument sales A: Roland Sackers stated NeuMoDx had minimal impact on operational expenses, with confidence in achieving 28.5% margin target and future margin improvement.

Q: Douglas Schenkel on portfolio optimization A: Thierry Bernard confirmed NeuMoDx phase-out and ongoing portfolio evaluation for pruning non-core assets.

Q: Patrick Donnelly on China market A: Thierry Bernard mentioned limited exposure but ongoing efforts to localize and leverage China's potential.

Q: Matthew Sykes on NGS business improvement A: Thierry Bernard cited QIAGEN's chemistry and bioinformatics fit with evolving NGS market, supporting demand in second half.

Q: Curtis Moiles on QuantiFERON guidance A: Thierry Bernard expressed confidence in beating QuantiFERON guidance, noting competitor product not new to market.